HTC Announcing $1 Million award for Endothelix, Inc. by the Texas Emerging Technology Fund
FOR IMMEDIATE RELEASE
July 21, 2006
Endothelix, Inc. was awarded the $1 million grant for the development of its low-cost, non-invasive VENDYS™ procedure, a new technology for the measurement of vascular reactivity, a marker of endothelial dysfunction, by monitoring temperature changes at one’s fingertips. Endothelix’s first technology was licensed from the Texas Heart Institute and the University of Texas Health Science Center in Houston. Researchers from the University of Houston, Baylor College of Medicine, and Texas A&M University are also actively involved with Endothelix.
“Endothelial dysfunction is the gateway to cardiovascular disease such as heart attack and stroke” explained Endothelix founder and CEO Dr. Morteza Naghavi, a former director of the Vulnerable Plaque Research Center at the University of Texas Health Science Center and the Texas Heart Institute in Houston. “Current technological difficulties have limited the use of endothelial function measurement to research laboratories. Endothelix’s mission is to bring this valuable test to patient care and enable physicians to detect their patient’s endothelial dysfunction and apply appropriate therapies” says Dr. Naghavi.
Endothelix, Inc. is one of three companies within the Gulf Coast RCIC’s area to be funded by the TETF. Other Gulf Coast recipients of the TETF funding are CorInnova Incorporated and itRobotics, all of which are HTC Client Companies.
The $200 million Texas Emerging Technology Fund, was created in June 2005 by Governor Rick Perry to assist small to mid-size technology companies to launch sooner, expedite the commercialization of new life-changing inventions out of the lab and into the hands of consumers and improve research at Texas universities.
HTC, selected in September 2005 to be the Gulf Coast RCIC for the TETF, is collaborating with the Greater Houston Partnership (GHP), Economic Development Organizations (EDO) within its 32-county region, area universities, and community volunteers. The Gulf Coast RCIC, the other six regional centers and the State-wide Texas Life Science Center are responsible for processing funding applications and supporting emerging technology companies.
“Houston Technology Center congratulates Endothelix, Inc. on receiving the TETF funding and welcomes the company as a new Client. We are encouraged to see the growing number of companies from the Gulf Coast region that are selected to receive the TETF grants. It is a testimony of the quality of research and development that is being accomplished in our area”, said Paul Frison, President and CEO of the Houston Technology Center.
The Gulf Coast RCIC is currently reviewing applications submitted for the fourth round of funding. Applications for the fifth round of funding may be submitted to the Gulf Coast RCIC until September 26, 2007, 10:00 a.m. CST. For detailed information about the Emerging Technology Fund, visit the Gulf Coast RCIC web site at www.gulfcoastrcic.org.
About the Houston Technology Center: Houston Technology Center (HTC), A non-profit 501(c)(3) corporation, is Greater Houston’s business accelerator and the largest technology business incubator in Texas. HTC accelerates the commercialization of emerging technology companies in Houston. A 501(C)(3) corporation and a center of entrepreneurship in Houston, HTC assists Houston-based entrepreneurs within several key sectors: Energy, Technology, Life Sciences, Nanotechnology and NASA-originated technologies. For more information visit www.houstontech.org.
About Endothelix, Inc.: Endothelix, a Houston-based Delaware corporation, is dedicated to bringing endothelial function measurement from research laboratories to the mainstream practice of medicine in a low-cost and operator-independent manner. Endothelial dysfunction is associated with several diseases such as cardiovascular disease, diabetes, renal failure, Alzheimer’s disease, and more. The immediate focus of the company is on early detection of cardiovascular disease and monitoring response to therapy. More information is available at www.endothelix.com.
For more information please contact:
Director, Gulf Coast RCIC